Cohen D J, Krumholz H M, Sukin C A, Ho K K, Siegrist R B, Cleman M, Heuser R R, Brinker J A, Moses J W, Savage M P
Cardiovascular Division, Beth Israel Hospital, Boston, MA 02215, USA.
Circulation. 1995 Nov 1;92(9):2480-7. doi: 10.1161/01.cir.92.9.2480.
Coronary stenting has been shown to improve initial success, reduce angiographic restenosis, and reduce the need for repeat revascularization compared with conventional balloon angioplasty (PTCA). Although previous studies have demonstrated that initial hospital costs for stenting are considerably higher than those for conventional PTCA, the impact of coronary stenting on long-term medical care costs remains unknown.
Between January 1991 and June 1993, 207 consecutive patients with symptomatic coronary disease requiring revascularization of a single coronary lesion were randomized to receive initial treatment by either PTCA (n = 105) or Palmaz-Schatz coronary stent implantation (n = 102) in the multicenter STRESS trial. Detailed resource utilization and cost data were collected for each patient's initial hospitalization and for any subsequent hospital visits for 1 year after randomization. Compared with conventional angioplasty, coronary stenting resulted in additional catheterization laboratory costs, increased vascular complications, and longer length of stay. Initial hospital costs were thus approximately $2200 higher for stenting than for PTCA ($9738 +/- 3248 versus $7505 +/- 5015; P < .001). Over the first year of follow-up, however, patients assigned to initial stenting were less likely to require rehospitalization for a cardiac condition and underwent fewer subsequent revascularization procedures. Follow-up medical care costs thus tended to be lower for stenting than for conventional angioplasty ($1918 +/- 4841 versus $3359 +/- 7100, P = .21). Nonetheless, cumulative 1-year medical care costs remained higher for patients undergoing initial stenting ($11,656 +/- 5674 versus $10,865 +/- 9073, P < .001). Even after adjustment for the higher incidence of vascular complications in the stent group, total 1-year costs were $300 higher for stenting than for balloon angioplasty.
Elective coronary stenting, as performed in the randomized STRESS trial, increased total 1-year medical care costs by approximately $800 per patient compared with conventional angioplasty. Future studies will be necessary to determine whether ongoing refinements in stent design, implantation techniques, and anticoagulation regimens can narrow this cost difference further by reducing stent-related vascular complications or length of stay.
与传统球囊血管成形术(PTCA)相比,冠状动脉支架置入术已被证明可提高初始成功率、减少血管造影显示的再狭窄,并减少重复血运重建的需求。尽管先前的研究表明,支架置入术的初始住院费用明显高于传统PTCA,但冠状动脉支架置入术对长期医疗费用的影响仍不清楚。
在1991年1月至1993年6月期间,在多中心STRESS试验中,207例有症状的冠状动脉疾病且需要对单一冠状动脉病变进行血运重建的连续患者被随机分配接受初始治疗,其中105例接受PTCA,102例接受Palmaz-Schatz冠状动脉支架置入。收集了每位患者初始住院以及随机分组后1年内任何后续住院就诊的详细资源利用和成本数据。与传统血管成形术相比,冠状动脉支架置入术导致导管实验室成本增加、血管并发症增多以及住院时间延长。因此,支架置入术的初始住院费用比PTCA高出约2200美元(9738±3248美元对7505±5015美元;P<.001)。然而,在随访的第一年,接受初始支架置入的患者因心脏疾病再次住院的可能性较小,且随后进行的血运重建手术较少。因此,支架置入术的随访医疗费用往往低于传统血管成形术(1918±4841美元对3359±7100美元,P=.21)。尽管如此,接受初始支架置入的患者1年累计医疗费用仍然较高(11,656±5674美元对10,865±9073美元,P<.001)。即使对支架组中较高的血管并发症发生率进行调整后,支架置入术的1年总费用仍比球囊血管成形术高出300美元。
在随机的STRESS试验中进行的择期冠状动脉支架置入术与传统血管成形术相比,每位患者1年的总医疗费用增加了约800美元。未来有必要进行研究,以确定支架设计、植入技术和抗凝方案的不断改进是否能通过减少与支架相关的血管并发症或住院时间进一步缩小这种成本差异。